ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AEZS Stock Price » AEZS Stock News

Aeterna Zentaris Share News

 Aeterna Zentaris (mm) Stock Price
AEZS Stock Price
 Aeterna Zentaris (mm) Stock Chart
AEZS Stock Chart
 Aeterna Zentaris (mm) Stock News
AEZS Stock News
 Aeterna Zentaris (mm) Company Information
AEZS Company Information
 Aeterna Zentaris (mm) Stock Trades
AEZS Stock Trades

FDA Fast Tracks Keryx Colorectal Cancer Drug, Shares Soar

DOW JONES NEWSWIRES Keryx Biopharmaceuticals Inc. (KERX) said the U.S. Food and Drug Administration has given fast-track designation to perifosine, its drug for treating colorectal cancer. Shares of the biopharmaceutical company jumped 25% to $3.43 in recent trading, while U.S.-traded shares of Keryx's Canadian partner Aeterna Zentaris Inc. (AEZ.T, AEZS) were recently up 23% to 99 cents. Drugs given fast-track designation are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs, Keryx said. They usually qualify for expedited review from the FDA. "We believe that commercialization of perifosine in this indication could potentially commence by mid-2012," said Chief Executive Ron Bentsur. Keryx said it expects to begin Phase III testing of the drug in the second quarter of this year, and it expects to complete the study in the second half of 2011. Keryx in December received fast-track status from the FDA for perifosine for the treatment of multiple myeloma. The treatment is licensed by Keryx from Aeterna for the U.S., Canada and Mexico. -By Nathan Becker, Dow Jones Newswires; 212-416-2855;;

Stock News for Aeterna Zentaris (AEZS)
08/09/201617:19:14Report of Foreign Issuer (6-k)
08/09/201616:30:00Aeterna Zentaris Reports Second Quarter 2016 Financial and Operating...
08/08/201608:30:00Aeterna Zentaris Expands Promotion of APIFINY® into Florida
08/01/201608:30:00Aeterna Zentaris and Rafa Laboratories Sign Exclusive License...
07/27/201608:30:00Aeterna Zentaris to Announce Second Quarter 2016 Financial and...
07/01/201608:30:00Aeterna Zentaris and Orient EuroPharma Co., Ltd. Sign Exclusive...
06/14/201617:00:00Aeterna Zentaris Announces IND Submission by Sinopharm A-Think
06/06/201617:00:00Aeterna Zentaris Reconfirms Commitment to LHRH-receptor Targeting...
05/23/201620:15:00Aeterna Zentaris Elects Ms. Carolyn Egbert as Independent Chair...
05/12/201612:15:44Amended Appointment of Agent for Service of Process and Undertaking...
05/10/201616:00:00Aeterna Zentaris Announces Election of Directors at 2016 Shareholders...
05/10/201611:40:06Report of Foreign Issuer (6-k)
05/09/201618:06:00Report of Foreign Issuer (6-k)
05/09/201618:04:21Report of Foreign Issuer (6-k)
05/09/201617:00:00Aeterna Zentaris Reports First Quarter 2016 Financial and Operating...
04/27/201616:05:00Aeterna Zentaris Acquires Exclusive U.S. Promotional Rights for...
04/26/201608:30:00Aeterna Zentaris to Announce First Quarter 2016 Financial and...
04/08/201615:00:00Aeterna Zentaris Mails Information Circular in Connection with...
04/01/201617:19:49Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)
04/01/201617:17:53Report of Foreign Issuer (6-k)

Aeterna Zentaris and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations